Shenzhen Hepalink Forecasts Up to 56% Lower Profit in 2025

MT Newswires Live

01/30

Shenzhen Hepalink Pharmaceutical Group (HKG:9989) said it expects 284 million yuan to 377 million yuan in attributable profit for 2025, a decrease of 42% to 56% from the 646.7 million yuan posted in 2024, according to a Hong Kong bourse filing Friday.

Basic earnings per share are expected to be between 0.1936 yuan and 0.2569 yuan, compared with 0.4408 yuan in 2024.

The company's financial results are due by the end of March.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2607019353"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2607019353\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2607019353?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-30 18:20","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2607019353","market":"fut","top_or_hot":-1,"title":"Shenzhen Hepalink Forecasts Up to 56% Lower Profit in 2025","media":"MT Newswires Live","content":"<html><body><p> <a href=\"https://laohu8.com/S/SHEZF\">Shenzhen Hepalink</a> Pharmaceutical Group (HKG:9989) said it expects 284 million yuan to 377 million yuan in attributable profit for 2025, a decrease of 42% to 56% from the 646.7 million yuan posted in 2024, according to a Hong Kong bourse filing Friday.</p><p>Basic earnings per share are expected to be between 0.1936 yuan and 0.2569 yuan, compared with 0.4408 yuan in 2024.</p><p>The company's financial results are due by the end of March.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Shenzhen Hepalink Forecasts Up to 56% Lower Profit in 2025</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nShenzhen Hepalink Forecasts Up to 56% Lower Profit in 2025\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time smaller\">2026-01-30 18:20</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html><body><p> <a href=\"https://laohu8.com/S/SHEZF\">Shenzhen Hepalink</a> Pharmaceutical Group (HKG:9989) said it expects 284 million yuan to 377 million yuan in attributable profit for 2025, a decrease of 42% to 56% from the 646.7 million yuan posted in 2024, according to a Hong Kong bourse filing Friday.</p><p>Basic earnings per share are expected to be between 0.1936 yuan and 0.2569 yuan, compared with 0.4408 yuan in 2024.</p><p>The company's financial results are due by the end of March.</p></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1191","symbol_name":"製藥","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2607019353","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2607019353","pubTimestamp":1769768436,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Shenzhen Hepalink Pharmaceutical Group  said it expects 284 million yuan to 377 million yuan in attributable profit for 2025, a decrease of 42% to 56% from the 646.7 million yuan posted in 2024, according to a Hong Kong bourse filing Friday.Basic earnings per share are expected to be between 0.1936 yuan and 0.2569 yuan, compared with 0.4408 yuan in 2024.The company's financial results are due by the end of March.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1191":"制药","09989":"海普瑞"},"translate_title":"深圳海普瑞预计2025年利润最多下降56%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"09989":1},"content_text":"Shenzhen Hepalink Pharmaceutical Group (HKG:9989) said it expects 284 million yuan to 377 million yuan in attributable profit for 2025, a decrease of 42% to 56% from the 646.7 million yuan posted in 2024, according to a Hong Kong bourse filing Friday.Basic earnings per share are expected to be between 0.1936 yuan and 0.2569 yuan, compared with 0.4408 yuan in 2024.The company's financial results are due by the end of March.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}